###### Strengths and limitations of this study

-   This is the first study that seeks to identify any candidate single nucleotide polymorphisms that help to predict differences in breathlessness intensity while on morphine.

-   This is a population-based study using rigorous methodologies.

-   The cohort used are taken from clinical practice across a range of clinical settings and countries.

-   There is no replication cohort in this study---this is a topic for further work.

-   This study has only sought signal from a bank of candidate genes.

Introduction {#s1}
============

Breathlessness that persists despite disease-modifying treatment (refractory breathlessness) is a major clinical problem internationally.[@R1] [@R2] Chronic causes include respiratory disease (mainly chronic obstructive pulmonary disease (COPD) and interstitial lung disease), cardiac failure, progressive neurological disorders, cancers and cachexia in any late-stage disease.[@R3] Symptom control is a key priority for people with a life-limiting illness as well as for their caregivers.[@R6]

Experimental studies of people with COPD and in healthy volunteers have shown that endogenous and exogenous opioids modulate the perception of breathlessness intensity without diminishing the ability to breathe during exercise or with resistive loads.[@R7] In phase III clinical trials, the regular and systematic use of low doses of morphine (≤30 mg morphine/24 h) have been shown to safely reduce chronic refractory breathlessness intensity by a clinically meaningful extent.[@R10]

In the only formal dose-ranging study of opioids for the reduction of breathlessness intensity, the opioid dose needed to relieve breathlessness is highly individual, with a threefold difference of the dose required to relieve breathlessness, and where there was only a weak association between the severity of breathlessness and the dose of low-dose, sustained-release morphine providing relief.[@R11] Clinicodemographic factors predicting response of breathlessness intensity to opioids from pooled data included higher baseline intensity of breathlessness and younger age.[@R15] In this analysis, breathlessness intensity was not predicted by the dominant aetiology of breathlessness, gender, functional status nor descriptors of the breathlessness.[@R15]

Clinically, large interindividual variations are also seen in the doses of opioids required to relieve pain in the palliative care population. The European Pharmacogenetic Opioid Study (EPOS), the largest such study in the world (n=2294), failed to find any single nucleotide polymorphisms (SNPs) from 112 candidate SNPs on 25 genes involved in opioid receptors, signalling, nor pain-modifying functions that explained any of the variations in the opioid dose required to achieve a symptomatic response to opioids for pain.[@R16] This was in contrast with smaller studies which had identified several SNPs purportedly influencing the dose--response relationship.[@R16] To date, no studies exploring genetic variability related to opioids and the palliation of refractory breathlessness have been conducted.

The aim of this hypothesis-generating, secondary analysis of the EPOS data is to identify possible candidate SNPs from a selection identified in the literature known to be associated with opioid pharmacology in order to inform future and prospective pharmacogenetic studies of the response of refractory breathlessness to opioids. This builds on the investigation of other key symptoms for people at the end of life including pain, nausea and cachexia from the same observational cohort.[@R16]

This study tests the null hypothesis that genetic variations in selected candidate SNPs related to opioid receptors, signalling or pain-modifying functions are not associated with the intensity of breathlessness in people already treated with opioids for pain, assuming a similar distribution of pain and breathlessness scores across the population, and that opioid doses had been titrated to clinical effect. Importantly, this study is not exploring SNPs for breathlessness per se, or any relationship between SNPs and *response* to opioids in breathlessness intensity because of its cross-sectional design, but instead, SNPs which may influence a relationship between breathlessness intensity scores and opioids in people already on opioids for pain.

Methods {#s2}
=======

Methods have been outlined in detail in previous papers from the group.[@R16]

Study setting {#s2a}
-------------

This cross-sectional study included 17 centres from 11 European countries.

In the subgroup of people using morphine with collected breathlessness intensity scores (n=838), 112 candidate SNPs in 25 genes ([table 1](#BMJOPEN2014006818TB1){ref-type="table"}) with a putative influence on opioid receptors, signalling or pain modulation were evaluated for any association with breathlessness intensity scores, controlling for key factors that may influence breathlessness intensity or response to opioids. This analysis was repeated separately for people on fentanyl (n=405) or oxycodone (n=429).

###### 

112 Predefined candidate single nucleotide polymorphisms (SNPs) in 25 genes with a putative influence on opioid receptors, signalling and pain modulation: OPRM1, OPRD1, OPRK1, ARRB2, GNAZ, HINT1, Stat6, ABCB1, COMT, HRH1, ADRA2A, MC1R, TACR1, GCH1, DRD2, DRD3, HTR3A, HTR3B, HTR2A, HTR3C, HTR3D, HTR3E, HTR1A, UGT2B7 or CNR1

                               Morphine (n=838)     Fentanyl (n=405)     Oxycodone (n=429)
  ---------------------------- -------------------- -------------------- --------------------
  Age (years)                  62.1 (12.1)          63.5 (12.6)          62.3 (12.3)
  Female gender                394 (47.0)           202 (49.9)           188 (43.8)
  Body mass index (kg/m^2^)    24.1 (4.7)           23.2 (4.6)           23.9 (4.3)
  Karnofsky\*                  60 (50--70)          60 (40--70)          70 (50--80)
  Time on opioids (months)\*   1 (0--4)             1 (0--4)             1 (0--4.5)
  24 hourly opioid dose\*      60 mg (40--120 mg)   50 µg (25 --75 µg)   60 mg (40--120 mg)

The population characteristics of the three cohorts of patients on opioids in the European Palliative Outcomes Study (mean (SD), median (IQR\*) or n (%)).

\*IQR=(Lower quartile−upper quartile).

Study participants {#s2b}
------------------

Inclusion criteria were: age 18 years or over; confirmed diagnosis of cancer; and regular use of a WHO step 3 opioid for moderate or severe pain related to the cancer or its treatment for more than 3 days. The only exclusion criterion was the inability to use the language spoken in the treating cancer centre.

Data collection {#s2c}
---------------

Between February 2004 and April 2008, cross-sectional phenotypic data were collected on the cohort including gender, age, weight, height, ethnicity, cancer diagnosis and sites of metastatic disease, the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30; V.3.0)[@R19] and performance status (Karnofsky Performance Status scale).[@R20] Data related to opioids included type of opioid, total opioid dose in the 24 h prior to blood sampling, duration of opioid therapy, and past use of other opioids. Breathlessness intensity was evaluated from question 8 in the EORTC QLQ-C30 on a four-point categorical verbal rating scale (not at all; a little; quite a bit; or very much) covering the person\'s experience of the symptom over the previous week, reflecting the sensory-perceptual experience of the American Thoracic Society\'s recent statement on the Mechanisms, Assessment and Management of Dyspnea.[@R21]

Specimen collection and analysis {#s2d}
--------------------------------

A single specimen of whole blood was collected in an EDTA tube at the time of questionnaire completion and stored at --80°C before batched shipping to the HUNT Biobank in Levanger, Norway. DNA was extracted using Puregene blood kit (Qiagen Science, Germantown, Maryland, USA) and using technology from Applied Biosystems (Foster City, California, USA): the genotyping was done using the SNPlex (dry DNA) Genotyping System; capillary electrophoresis; gene mapping (V.4.0 software); and two SNPs (rs4680 and rs1045642) were extracted using TaqMan SNP allelic discrimination.

Data analysis {#s2e}
-------------

Separate analyses were conducted for each of three mutually exclusive populations (those who were prescribed only one opioid: morphine, oxycodone, or fentanyl), and for each of four modes of inheritance (dominant, recessive, codominant and overdominant). For each population, SNPs that were not in Hardy-Weinberg equilibrium, or had minor allele frequencies (\<5%) were removed from the analysis, leaving 112, 105 and 104 SNPs of interest in each of the morphine, oxycodone and fentanyl populations, respectively. Univariable associations between each SNP and the four-point categorical rating scale for breathlessness were determined using Fisher\'s exact test. To control the overall family-wise type I error rate (FWE) within each mode of inheritance and for each opioid, we used Benjamini-Hochberg (BH) multiple hypothesis testing with a false discovery rate (FDR) set at 20%.[@R22]

The associations between breathlessness and any SNPs identified as significant using the BH procedure, within each mode of inheritance and each opioid prescribed, were then examined using multivariable ordinal logistic regression, clustering over country, and adjusting for age, gender, BMI, Karnofsky status, time on opioids, opioid dose, pain levels and the SNPs identified by the BH procedure. In order to fit the model, it was necessary to remove extraneous SNPs in high linkage disequilibrium, with .[@R23] The model reported did not violate the proportional odds assumption for any of the three opioids studied. For these analyses, a p value less than 0.05 (two-tailed) is considered statistically significant.

All analyses were conducted using Stata V.13.1 (Statacorp, Texas, USA).

A properly constituted Research Ethics Committee at each participating site approved the study, and each participant provided written, informed consent.

The study is reported according to the STrengthening the REporting of Genetic Association Studies (STREGA) guidelines.[@R24]

Results {#s3}
=======

The clinico-demographic factors for the 1672 participants in this substudy are outlined in [table 1](#BMJOPEN2014006818TB1){ref-type="table"} for the cohorts taking each of the three opioids.

Eight hundred and thirty-eight people were taking morphine in whom viable samples were available for 588. For these people, four variants on the β2 arrestin gene (*ARRB2*) and one on the 5-hydroxytryptamine type 3B (*HTR3B* rs7103572) gene were associated in univariable analyses with breathlessness intensity ([table 2](#BMJOPEN2014006818TB2){ref-type="table"}). The genotypic frequency of each variant is also outlined ([table 2](#BMJOPEN2014006818TB2){ref-type="table"}). Additionally, morphine dose and worsening functional (Karnofsky) status were significantly associated with more intense breathlessness in univariable analyses ([table 3](#BMJOPEN2014006818TB3){ref-type="table"}). In the multivariable model, three of the *ARRB2* variants were excluded as all variants were in high linkage disequilibrium with Lewontin\'s[@R25] normalised linkage disequilibrium parameter for each pair of SNPs (where a value of indicates independence and complete dependence of SNP frequencies).

###### 

The significant single nucleotide polymorphisms for the recessive mode of inheritance for morphine users (Fisher\'s exact test) and the frequency of these minor alleles

  Morphine             p Value   Variant         n (%)
  -------------------- --------- --------------- -----------
  *ARRB2*\_rs3786047   0.0010    AA vs (AG+GG)   77 (9.6)
  *ARRB2*\_rs2036657   0.0045    GG vs (AG+AA)   79 (9.9)
  *ARRB2*\_rs2271167   0.0052    AA vs (AG+GG)   77 (9.9)
  *ARRB2*\_rs1045280   0.0069    CC vs (CT+TT)   81 (10.1)
  *HTR3B\_*rs7103572   0.0070    TT vs (CC+TC)   48 (8.2)

###### 

Association between breathlessness and confounders for the recessive mode of inheritance in the morphine population

                                                Univariable analysis          Multivariable analysis                                 
  --------------------------------------------- ----------------------------- ------------------------ ----------------------------- -----------
  *HTR3B*\_rs7103572                            **2.86** (**1.31 to 6.21)**   **0.008**                **2.86** (**1.46 to 5.62)**   **0.002**
  *ARRB2*\_rs1045280                            0.846 (0.59 to 1.22)          0.36                     0.97 (0.62 to 1.62)           0.89
  Age (per year)                                1.00 (0.99 to 1.01)           0.90                     1.00 (0.98 to 1.02)           0.73
  Male gender                                   1.05 (0.84 to 1.31)           0.69                     1.06 (0.78 to 1.45)           0.70
  Body mass index (per 1 kg/m^2^)               1.03 (0.98 to 1.08)           0.32                     1.03 (0.97 to 1.09)           0.39
  Karnofsky status (per 1 point)                **0.83** (**0.75 to 0.92)**   **\<0.001**              **0.83** (**0.72 to 0.96)**   **0.011**
  Time on opioids (per month)                   0.99 (0.97 to 1.00)           0.17                     0.99 (0.97 to 1.00)           0.15
  Morphine daily dose (per 100 mg increments)   **1.00** (**1.00 to 1.00)**   **0.17**                 1.00 (1.00 to 1.00)           0.469
  Pain                                          **1.19** (**1.03 to 1.39)**   **0.022**                1.13 (0.84 to 1.52)           0.41

Significance was only maintained for the *HTR3B* (rs7103572) and functional status ([table 3](#BMJOPEN2014006818TB3){ref-type="table"}). There was no interaction between *HTR3B* (rs7103572) and opioid dose. There were no significant findings in the oxycodone or fentanyl cohorts.

The HTR3B (rs7103572) genotype frequency (TT) was 8.2% of participants, with 52.8% CC and 39.1% CT. The allele frequency was 72.3% (C) and 27.7% (T). Other HTR3B SNPs tested included rs11214763, rs11606194, rs1176744, rs2276307, rs3782025, rs1672717 and rs7943062.

Discussion {#s4}
==========

In this study, people taking morphine for cancer pain and with both rs7103572 allele variants of the *5HT3B* gene were three times more likely to have more intense breathlessness having controlled for other available factors. This finding was not mirrored in those taking oxycodone or fentanyl.

Breathlessness, like pain, is a phenotype with complex biological interactions.[@R16] Studies have shown only weak associations between the underlying aetiology of breathlessness, the descriptors of sensation and a tailored treatment for breathlessness.[@R26] The degree of physiological impairment (such as hypoxaemia or forced expiratory volume in 1 s) and a person\'s subjective sensation of breathlessness are weakly correlated and do not explain much of the interindividual and intraindividual variations observed with the subjective sensation of breathlessness.[@R27] Therefore, other factors need to be identified that help to understand the variations in the benefits and toxicities of people\'s clinical responses. Identifying potential factors associated with response, such as the *HTR3B*, has the potential to help reconcile clinical experience with objective factors that explain population differences. It is likely that several factors contribute to the reported threefold variation in breathlessness response to morphine observed in the dose titration study.[@R11] Other, as yet unknown factors, must be contributing to this variation in response to opioids, so any factor that helps to unravel variations in response of breathlessness to opioids is likely to be of value to clinicians and researchers given the paucity of such factors currently. These current findings of one potential SNP would form the basis of a prospective study in which opioids were introduced to people with refractory breathlessness in order to determine if this SNP could be used to predict response.

Are these findings biologically plausible? The HTR3B gene is responsible for the synthesis of the serotonergic 5-hydroxytryptamine (5HT)~3B~ subtype receptor. There is at least one potential explanation of how opioids may influence the serotonergic system. The original recognition that there was more than one 5HT receptor was, in part, by demonstrating that morphine was a weak 5HT receptor antagonist,[@R28] and was initially, therefore, named the 'M' variant. Cocaine and methadone were simultaneously identified as weak 5HT antagonists.[@R28] Recently, the M variant was recognised as the 5HT~3~ receptor.[@R29] Even recent work has now identified five variants of 5HT~3~ receptors, the most prevalent of which are A and B. The gene coding for 5HT~3B~ (*HTR3B*) is found on chromosome 11. The 5HT~3B~ receptors are found throughout the brain except the cerebellum.[@R30] While morphine is an inhibitor of the orthosteric ligand binding site of the 5HT~3~ ion channel complex, by contrast, fentanyl appears not to have an effect on 5HT~3~ receptors.[@R31] It is therefore biologically plausible that genetic variations in 5HT~3B~ may variably modulate morphine-related changes in breathlessness perception while fentanyl has no effect. This hypothesis also supports a recent study showing that another SNP of *HTR3B*, rs227607 is associated with myalgia score in statin users.[@R32]

Worsening performance status was the only other factor that was associated with more intense breathlessness in the multivariable analyses. Previous population-based studies have demonstrated worsening breathlessness as functional status deteriorates,[@R33] even in the absence of demonstrable cardiorespiratory disease.[@R5] For some patients, it appears that breathlessness is induced by a physical inability to breathe because of the loss of respiratory muscles.[@R34]

This is a study in a large clinical population using opioids for pain where a range of symptoms were recorded. Symptom assessment used validated tools,[@R19] although any interaction between symptoms is poorly understood.[@R35] The study relies on a Likert scale for measuring breathlessness. Widely used assessment tools including EORTC QLQC 30 and 15, and the Functional Assessment Cancer Treatment tools use Likert scales as their measure.[@R34] [@R36] Symptoms are measured over the last week using EORTC QLQ C-30, but medications reported over the last 24 h. It is unlikely that this difference has a material effect on the relationship being sought in this exploratory study. Although visual analogue scales, or Borg scales, may be preferable in this population, Likert scales for reviews of large numbers of symptoms are a reasonable approach.[@R37] It is also worth noting that these screening tools make no distinction between the affective component of breathlessness (unpleasantness) and its intensity (severity).[@R27] Any prospective study would need to separate these two components of breathlessness and reflect the person\'s emotional response.

Strengths of the study {#s4a}
----------------------

Many genetic association studies have not been reproducible. By contrast, the current study has several key strengths that increase confidence in the finding that a particular SNP might influence morphine-induced modulation of the sensation of breathlessness: A plausible biological mechanism;Large number of patients (including enough to include relevant clinical and demographic covariates in the analytic models);A study population broadly representative of people with advanced cancer;A large number of genes and candidate SNPs;Rigorous statistical methods to deal with the problem of multiplicity;Seeking a signal that is sufficient to be clinically meaningful;Use of well-validated assessment tools in rigorously translated versions for the participating countries.

Limitations {#s4b}
-----------

The study did not specify a particular mode of inheritance as primary, and therefore, our results do not control the FWE within the population. The study addressed this by creating sensitivity analyses that aggregated all comparisons for different modes of inheritance with each population and applied the BH procedure for multiple comparisons. As such, the study did not find any other significant SNPs until the FDR was set at 50% or greater.

This study only explored individual candidate SNPs and did not explore gene--gene interactions. A negative result does not rule out important SNPs on other parts of candidate genes or on other genes. The study does not contribute to candidate SNPs for the perception of breathlessness itself, only the degree of perception of breathlessness while on opioids for pain.

The change in symptom severity in this cross-sectional study population is unknown, and we are therefore unable to draw conclusions about breathlessness *response* to opioids. Only longitudinal studies before and after the introduction of opioids for breathlessness can fully answer this question. Some respondents with breathlessness may have partially responded to opioids for the intensity of their breathlessness, and be much worse without them, others may not have responded to opioids at all, and yet others with no breathlessness may have had none prior to starting opioids.

Implications for further research {#s4c}
---------------------------------

There is a need to replicate these findings in a similar independent cohort. There would be an argument for using one of the newer, more comprehensive measures of breathlessness that includes measures of severity, unpleasantness and the person\'s emotional response.[@R38] [@R39] Using such measurement tools would allow for a more nuanced exploration of the response to opioids for breathlessness.

Genome-wide association studies may identify genetic variations that are important in the explanation of varying responses of breathlessness to opioids as these studies become more affordable.

Conclusions {#s5}
===========

This large, exploratory study identified one SNP associated with higher levels of breathlessness in people taking morphine for pain, but not in those taking fentanyl or oxycodone. The study does not help to understand any genetic variations associated with the perception of breathlessness per se, but provides a candidate SNP for further evaluation in prospective studies of people before and after morphine is introduced to reduce the perception of breathlessness.
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